(Q37981898)

26 August 2017

0 references

Solifenacin for overactive bladder: a systematic review and meta-analysis (English)

1 reference

26 August 2017

1 reference

Deyi Luo

1

1 reference

26 August 2017

Liangren Liu

2

1 reference

26 August 2017

Ping Han

3

1 reference

26 August 2017

Qiang Wei

4

1 reference

26 August 2017

Hong Shen

5

1 reference

26 August 2017

publication date

7 February 2012

1 reference

International Urogynecology Journal and Pelvic Floor Dysfunction

26 August 2017

published in

1 reference

26 August 2017

volume

23

1 reference

26 August 2017

issue

8

1 reference

26 August 2017

page(s)

983-991

1 reference

The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00192-011-1641-7

How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00192-011-1641-7

The current and future burden and cost of overactive bladder in five European countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00192-011-1641-7

A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00192-011-1641-7

Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double-blind, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00192-011-1641-7

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00192-011-1641-7

Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00192-011-1641-7

Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00192-011-1641-7

Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00192-011-1641-7

Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00192-011-1641-7

Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00192-011-1641-7

Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00192-011-1641-7

Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00192-011-1641-7

Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00192-011-1641-7

Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00192-011-1641-7

Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00192-011-1641-7

Role of muscarinic receptor antagonists in urgency and nocturia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00192-011-1641-7

Efficacy of antimuscarinic therapy for overactive bladder with varying degrees of incontinence severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00192-011-1641-7

Pharmacologic management of overactive bladder: practical options for the primary care physician

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00192-011-1641-7

The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00192-011-1641-7

Muscarinic receptor antagonists in the treatment of overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00192-011-1641-7

Muscarinic receptor antagonists for overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00192-011-1641-7

Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults

21 January 2018

1 reference

12 December 2020

Evaluating and managing constipation in the elderly

1 reference

12 December 2020

Treatment Outcomes in the STAR Study: A Subanalysis of Solifenacin 5 mg and Tolterodine ER 4 mg

1 reference

12 December 2020

Newer agents for the management of overactive bladder.

1 reference

12 December 2020

Overactive bladder: recognition requires vigilance for symptoms.

1 reference

12 December 2020

Muscarinic receptor subtypes and smooth muscle function

1 reference

12 December 2020

10.1007/S00192-011-1641-7

Identifiers

DOI

1 reference

26 August 2017

1 reference